Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00321477 · ClinicalTrials.gov registry record · Phase 2
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT00321477 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 160 participants.
The verdict
NCT00321477, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
This is a Phase IIa study to evaluate the efficacy, safety and tolerability of GW679769 vs placebo on symptoms of urgency with urge incontinence, frequency and nocturia associated with overactive bladder in women.
Interventions
- DRUG GW679769 oral tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2005-12 |
| Est. Completion | 2007-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00321477
The ClinicalTrials.gov registry entry for NCT00321477 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GW679769 oral tablets is the first listed.
NCT00321477 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00321477 about?
NCT00321477 is a clinical study titled "A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder". This is a Phase IIa study to evaluate the efficacy, safety and tolerability of GW679769 vs placebo on symptoms of urgency with urge incontinence, frequency and nocturia associated with overactive bladder in women.
What is the current status of trial NCT00321477?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2005-12. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00321477?
The interventions under investigation include: GW679769 oral tablets (DRUG).
Who is sponsoring clinical trial NCT00321477?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.